The diversity and dynamics of tumor-associated macrophages in recurrent glioblastoma

Frontiers in Immunology

Immunology

Yu Jiang¹  Gao Zhang²  Shiyou Wei³  Lingyun Zhang⁴ 

[1] Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China;Faculty of Dentistry, The University of Hong Kong, Sai Ying Pun, Hong Kong, Hong Kong SAR, China;Institute of Thoracic Oncology and Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China;Institute of Thoracic Oncology and Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China;School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China;

关键词: recurrent glioblastoma;    tumor microenvironment;    immunotherapy;    microglia;    monocyte-derived macrophages;    single-cell;   

DOI  :  10.3389/fimmu.2023.1238233

 received in 2023-06-11, accepted in 2023-08-21,  发布年份 2023

来源: Frontiers

【 摘 要 】

Despite tremendous efforts to exploit effective therapeutic strategies, most glioblastoma (GBM) inevitably relapse and become resistant to therapies, including radiotherapy and immunotherapy. The tumor microenvironment (TME) of recurrent GBM (rGBM) is highly immunosuppressive, dominated by tumor-associated macrophages (TAMs). TAMs consist of tissue-resident microglia and monocyte-derived macrophages (MDMs), which are essential for favoring tumor growth, invasion, angiogenesis, immune suppression, and therapeutic resistance; however, restricted by the absence of potent methods, the heterogeneity and plasticity of TAMs in rGBM remain incompletely investigated. Recent application of single-cell technologies, such as single-cell RNA-sequencing has enabled us to decipher the unforeseen diversity and dynamics of TAMs and to identify new subsets of TAMs which regulate anti-tumor immunity. Here, we first review hallmarks of the TME, progress and challenges of immunotherapy, and the biology of TAMs in the context of rGBM, including their origins, categories, and functions. Next, from a single-cell perspective, we highlight recent findings regarding the distinctions between tissue-resident microglia and MDMs, the identification and characterization of specific TAM subsets, and the dynamic alterations of TAMs during tumor progression and treatment. Last, we briefly discuss the potential of TAM-targeted strategies for combination immunotherapy in rGBM. We anticipate the comprehensive understanding of the diversity and dynamics of TAMs in rGBM will shed light on further improvement of immunotherapeutic efficacy in rGBM.

【 授权许可】

Unknown   
Copyright © 2023 Zhang, Jiang, Zhang and Wei